News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Investor Alerts Year All Years 2022 2021 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard 06.21.2022 Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers Read More > 06.02.2022 Nuvalent to Present at the 2022 Jefferies Healthcare Conference Read More > 05.12.2022 Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results Read More > 04.08.2022 Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 Read More > 04.07.2022 Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference Read More > Show 5102550100 per page«123456»
